Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals has informed the BSE that its trading window for dealing in company securities will be closed from October 1, 2025 until 48 hours after the declaration of its Unaudited Financial Results for the quarter ended September 30, 2025 (Q2 FY26). The restriction applies to promoters, promoter group members, directors, KMPs, insiders, designated persons, connected persons and their immediate relatives. The closure is being done as per SEBI's Insider Trading Regulations (PIT) and the company's internal code of conduct. The date of the board meeting to approve Q2 results will be announced separately.
This is a routine SEBI compliance filing ahead of the company's Q2 FY26 results and carries no direct impact on shareholders or the stock price. It simply restricts insiders from trading during the pre-results silent period to prevent any potential insider trading.